The design plan should simultaneously consider observation periods, doses, and observation indicators for both tests.
Suggested Reading
- What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can…
- How should the evaluation of new items in the endpoint table be considered after the implementation of the new…
- GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests…
- For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation…
- GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which…
- Why is the extraction period typically 24 hours in China for cytotoxicity testing?
- What factors may affect biocompatibility risk when using biological test data from similar devices for…
- Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,…
- Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation?
- Do all medical devices require chemical characterization?
- How is the endotoxin limit for wound dressing products determined?